Ahlskog J E
Department of Neurology, Mayo Clinic Rochester, MN 55905, USA.
Mayo Clin Proc. 1996 Jul;71(7):659-70. doi: 10.1016/S0025-6196(11)63004-8.
A variety of medical treatment strategies have been proposed as a means of slowing the progression of Parkinson's disease. This includes administration of selegiline (deprenyl) therapy, early use of bromocriptine or pergolide, and delay of levodopa therapy or restriction of the dose. There is no compelling evidence supporting the use of any of these treatment strategies for this purpose. Carbidopa-levodopa remains the most potent medication for symptomatic treatment of Parkinson's disease. Although starting levodopa therapy with the controlled-release formulation is advocated, this does not appear to have any major advantages over standard carbidopa-levodopa. Further studies are needed to identify other means of halting the progression of Parkinson's disease.
人们已经提出了多种医疗治疗策略，作为减缓帕金森病进展的一种手段。这包括使用司来吉兰（丙炔苯丙胺）治疗、早期使用溴隐亭或培高利特，以及延迟左旋多巴治疗或限制剂量。没有令人信服的证据支持为此目的使用这些治疗策略中的任何一种。卡比多巴-左旋多巴仍然是治疗帕金森病症状最有效的药物。虽然提倡开始使用控释制剂进行左旋多巴治疗，但与标准的卡比多巴-左旋多巴相比，这似乎没有任何主要优势。需要进一步研究以确定其他阻止帕金森病进展的方法。
